Association of Polymorphism rs2736990 of the α-Synuclein Gene with Metabolic Syndrome Among the Population of Kazakhstan with Arterial Hypertension.

Background: The prevalence of metabolic syndrome (MetS) in Kazakhstan reaches 40%. The presence of an association between certain genetic markers and the development of MetS will allow more accurately determining the cardiovascular risk for patients with hypertension and personalizing preventive recommendations. Methods: The purpose of the study was to investigate the presence of an associative relationship between various polymorphisms of the α-synuclein gene and the development of MetS in Kazakh people with high blood pressure. Four hundred twenty-six patients were examined [age 49.5 (interquartile range 42.5-56), men 209 (49.1%), women 217 (50.9%)]. Standard clinical and laboratory methods were used. AutoMate Express™ and OpenArray technologies were used for DNA extraction and further genotyping. Patients with MetS made up the ms+ group, those without MetS-the ms- group. Results: In the examined patients, four polymorphisms of the α-synuclein gene were identified: rs356219, rs2736990, rs11931074, and rs2737029. According to the results of statistical analysis, the frequency and risk of developing MetS did not depend on different alleles and inheritance types of polymorphisms rs356219 and rs11931074. The minor allele of polymorphism rs2737029 exhibits a higher frequency in patients with arterial hypertension accompanied by MetS, although the specific model of inheritance remains to be conclusively determined. Conclusions: In carriers of the minor allele of polymorphism rs2736990, the risk of MetS increases 1.3 times, regardless of age and gender [odds ratio (95% confidence interval) = 1.36 (1.01-1.82), P < 0.05], the inheritance model is log-additive.

Retraction Note: Systematisation of biological protectors for managing the metabolic syndrome development.

[This retracts the article DOI: 10.1007/s40200-021-00883-3.].

Systematisation of biological protectors for managing the metabolic syndrome development.

BACKGROUND: Metabolic syndrome (MS) is becoming a major health risk in the world. Disorders of homeostasis are a trigger for MS and subsequent cardiometabolic diseases (CMDs). Its physiological role can be supported by biological protectors (BP). The purpose of this study is to develop a BP system for managing the MS development. METHODS: Within the framework of the case-control study, 3000 participants aged 20-60 years formed 2 groups: the main group and the control group. RESULTS: The study compared traditional markers of oxidative stress, chronic inflammation, and insulin resistance, which reflect the state of homeostasis. The BP system, proposed based on the concept of maintaining homeostasis, offers the following points for investigating the possibilities of therapeutic intervention: confronting dysregulation of homeostasis, resisting chronic inflammation and oxidative stress, resisting the consequences of disturbed homeostasis. This approach not only contributed to the understanding of general biological processes, but also provided a targeted search and development of BP to maintain the stability of homeostasis with MS. CONCLUSIONS: The study results provided insight into new opportunities in the MS management.